Lilly and Merck pair ‘breakthrough’ therapies in latest cancer collaboration
Damian Garde
Eli Lilly and Merck are expanding their oncology partnership to study a combination of the former's top cancer prospect with the latter's blockbuster immunotherapy.
FierceBiotech ...
Amgen takes to Europe with its Humira biosimilar
Damian Garde
Amgen submitted its copy of AbbVie's blockbuster Humira to European regulators, angling to siphon revenues from the world's top-selling drug as rivals develop biosimilars ...
Employee No. 1: Doug Williams launches exosome R&D player Codiak Bio with $80M-plus
John Carroll
Doug Williams is now happy to reveal just why he stepped aside four months ago as R&D chief of Biogen. Last July, Williams signed on as "employee number one" ...
Merck may appeal to Supreme Court after again losing fight to protect Cubicin patents
Eric Palmer
Merck & Co. is running low on options after a federal appeals court Thursday again declined to back four patents that would have held at bay for 5 more years generics ...
Daiichi Sankyo’s cancer drug wins the FDA’s coveted ‘breakthrough’ tag
Damian Garde
Daiichi Sankyo picked up the FDA's breakthrough therapy designation for a Phase III cancer drug, putting it in line for preferential access to agency experts as it ...
Allergan pays $125M to rid itself of marketing charges tied to Warner Chilcott
Eric Palmer
Allergan has been trying for months to resolve bribery allegations that came with its $ 8.5 billion buyout of Warner Chilcott and now will do that with a plea deal ...
U.K. cost gatekeeper says ‘OK’ to Merck’s Keytruda for advanced skin cancer
Emily Wasserman
Merck's Keytruda got a green light from the U.K.'s cost effectiveness gatekeeper to treat patients with advanced skin cancer, chalking up another victory as ...
HIV activists join Janssen’s story-focused Prezcobix effort
Beth Snyder Bulik
Some heavy-hitting HIV activists have signed on to Janssen's ongoing "Wisdom" campaign, headlining a share-your-story campaign for people living with ...
COMMENTARY: Why would Martin Shkreli hike an old drug price by 5000%? Only a ‘moron’ would ask
John Carroll
FierceBiotech News
Nabriva pulls off a down-sized IPO, raising $92M for antibiotic R&D
Damian Garde
Antibiotics biotech Nabriva Therapeutics executed a $ 92.3 million IPO, pricing well below its projected range but scraping together the funds it needs to start a Phase ...